Breast Cancer: Diagnosis and Staging

Breast Cancer: Risks & Alerts - Spotting Trouble Early

• Major Risk Factors:
  • Non-Modifiable:
    • Age (↑ risk >50 yrs), Female sex
    • Family Hx (1st degree), BRCA1/BRCA2 mutations
    • Personal Hx of breast Ca, LCIS, ADH
    • Early menarche (<12 yrs), Late menopause (>55 yrs)
    • Dense breast tissue
  • Modifiable:
    • Nulliparity or late first child (>30 yrs)
    • No breastfeeding
    • Combined HRT, OCPs (slight risk)
    • Obesity (postmenopausal), Alcohol, Radiation exposure
• Clinical Alerts (Symptoms):
  • Painless lump (most common presentation)
  • Nipple changes: inversion/retraction, spontaneous bloody/serous discharge, Paget’s disease (eczematous changes)
  • Skin changes: dimpling (peau d’orange), tethering, erythema, ulceration
  • Axillary or supraclavicular lymphadenopathy
  • Breast asymmetry, contour changes, persistent pain (less common)

⭐ Most common site of breast cancer: Upper Outer Quadrant (UOQ).

Breast Cancer: Detective Work - Confirming Suspicions

• Screening Methods:
  • Mammography: Annually for women aged >40-45 years (guidelines vary).
  • Clinical Breast Exam (CBE): Part of routine check-ups.
  • Breast Self-Exam (BSE): Promotes awareness.
• Diagnostic Pathway:

  ⭐ Triple Assessment (Clinical exam, Imaging, Pathology/Biopsy) is key for diagnosis of palpable breast lumps.

*   **Imaging Insights**:
    *   Mammography: Detects masses, architectural distortion, microcalcifications. BI-RADS score guides management.
    *   Ultrasound: Differentiates solid vs. cystic lesions; primary tool <**35** yrs; guides biopsy.
    *   MRI: High-risk screening; assesses extent, multifocality, response to neoadjuvant chemotherapy.
*   **Pathology Confirmation**:
    *   Core Needle Biopsy (CNB): **Gold standard** for diagnosis. Provides tissue for histology, grade, and receptor status (ER, PR, HER2).
    *   FNAC: Limited; cannot assess invasiveness.

• Staging: Based on TNM classification (Tumor size, Nodal status, Metastasis).

Breast Cancer: Lab Deep Dive - Types & Traits

• Histopathology (Biopsy):
  • Invasive Ductal Carcinoma (IDC) NOS: Most common (~75%). Gritty, stellate appearance.
  • Invasive Lobular Carcinoma (ILC): ~10-15%. "Indian file" pattern (single cells in rows), often multifocal/bilateral.
  • Others: Tubular, Mucinous (Colloid), Medullary, Papillary.
• Key Receptors & Markers (IHC Panel):
  • Estrogen Receptor (ER)
  • Progesterone Receptor (PR)
  • HER2/neu (Human Epidermal growth factor Receptor 2)
  • Ki-67 (Proliferation index)
• Molecular Subtypes (Prognostic & Predictive):
  • Luminal A: ER+/PR+, HER2-, Low Ki-67. Best prognosis.
  • Luminal B: ER+/PR+, HER2+ OR (HER2- & High Ki-67).
  • HER2 Enriched: ER-/PR-, HER2+.
  • Basal-like (TNBC): ER-/PR-, HER2-.

⭐ Triple-negative breast cancer (TNBC) - ER negative, PR negative, HER2 negative - generally has the poorest prognosis among common subtypes.

Breast Cancer: Staging Showdown - Sizing Up the Foe

• TNM System (AJCC 8th Ed.): Key for prognosis & therapy.
  • T (Tumor Size):
    • Tis: In situ
    • T1: ≤ 2 cm (T1mi ≤ 0.1 cm; T1a >0.1-0.5 cm; T1b >0.5-1 cm; T1c >1-2 cm)
    • T2: > 2 cm - ≤ 5 cm
    • T3: > 5 cm
    • T4: Chest wall/skin invasion; inflammatory (T4d)
  • N (Nodes):
    • N0: No regional LN
    • N1: Mobile ipsilateral axillary
    • N2: Fixed axillary OR isolated internal mammary (clinically apparent)
    • N3: Infraclavicular/supraclavicular/internal mammary + axillary
  • M (Metastasis):
    • M0: No distant
    • M1: Distant
• Staging Types: Clinical (cTNM), Pathological (pTNM).

⭐ Axillary lymph node status is the single most important prognostic factor in early-stage, operable breast cancer.

High‑Yield Points - ⚡ Biggest Takeaways

• Triple assessment (clinical exam, imaging, pathology) is vital for diagnosis.
• Mammography is key for screening (>40 yrs); USG for younger or dense breasts.
• MRI aids high-risk screening, staging, and assessing NACT response.
• Core needle biopsy is the gold standard for definitive histological diagnosis.
• Staging uses the TNM system; pathological staging is most accurate.
• ER, PR, and HER2/neu status are crucial for prognosis and guiding therapy.
• Axillary lymph node status remains the single most important prognostic factor.